First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

NCT03399669 ·Status: UNKNOWN ·Phase: PHASE2

First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker

NCT00455936 ·Status: COMPLETED ·Phase: PHASE3

Third-line Treatment of Gefitinib in NSCLC Patients

NCT01933347 ·Status: COMPLETED ·Phase: PHASE2

Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

NCT01203917 ·Status: COMPLETED ·Phase: PHASE4

A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations

NCT01310036 ·Status: COMPLETED ·Phase: PHASE2

Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)

NCT00452244 ·Status: COMPLETED ·Phase: PHASE2

Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer

NCT03460275 ·Status: UNKNOWN ·Phase: PHASE2

Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors

NCT02447419 ·Status: COMPLETED ·Phase: PHASE2

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

NCT06376084 ·Status: ACTIVE_NOT_RECRUITING

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

NCT05920135 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

NCT02374645 ·Status: COMPLETED ·Phase: PHASE1

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

NCT03787992 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

NCT02088112 ·Status: COMPLETED ·Phase: PHASE1

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

NCT03856697 ·Status: UNKNOWN ·Phase: PHASE3

A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test

NCT02738684 ·Status: UNKNOWN

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

NCT03516214 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy

NCT01485809 ·Status: COMPLETED ·Phase: PHASE2

Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)

NCT01931306 ·Status: APPROVED_FOR_MARKETING

Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI

NCT04510415 ·Status: TERMINATED ·Phase: PHASE1

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

NCT02108964 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

NCT03267654 ·Status: UNKNOWN ·Phase: PHASE2

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

NCT03861156 ·Status: COMPLETED ·Phase: PHASE2

Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA

NCT02629523 ·Status: COMPLETED ·Phase: PHASE2

Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

NCT06674343 ·Status: RECRUITING ·Phase: PHASE3

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

NCT01665417 ·Status: UNKNOWN ·Phase: PHASE4